| Wu CW |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=None ------>paper_class3=1 ------>paper_class2=3 ------>vol=65 ------>confirm_bywho=cmshih ------>insert_bywho=fordmai ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=384 ------>medlineContent= ------>unit=E0103 ------>insert_date=20080413 ------>iam=3 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=62 ------>journal_name=Chemistry (The Chinese Chemical Society, Taipei) ------>paper_name=The Application of Green Chemistry in Pharmaceutical Chemistry ------>confirm_date=20080413 ------>tch_id=096024 ------>pmid=19629979 ------>page1=377 ------>fullAbstract=PURPOSE: To investigate the effectiveness of a polydisulfide-based biodegradable macromolecular contrast agent, (Gd-DTPA)-cystamine copolymers (GDCC), in assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). MATERIALS AND METHODS: Breast cancer xenografts in mice were injected with indocyanine green and irradiated with a laser. The efficacy was assessed using DCE-MRI with GDCC of 40 kDa (GDCC-40) at 4 hours and 7 days after the treatment. The uptake of GDCC-40 by the tumors was fit to a two-compartment model to obtain tumor vascular parameters, including fractional plasma volume (f(PV)), endothelium transfer coefficient (K(PS)), and permeability surface area product (PS). RESULTS: GDCC-40 resulted in similar tumor vascular parameters at three doses, with larger standard deviations at lower doses. The values of f(PV), K(PS), and PS of the treated tumors were smaller (P < 0.05) than those of untreated tumors at 4 hours after the treatment and recovered to pretreatment values (P > 0.05) at 7 days after the treatment. CONCLUSION: DCE-MRI with GDCC-40 is effective for assessing tumor early response to dye-enhanced photothermal therapy and detecting tumor relapse after the treatment. GDCC-40 has a potential to noninvasively monitor anticancer therapies with DCE-MRI. ------>tmu_sno=None ------>sno=17489 ------>authors2=Liu SC ------>authors3=Mai FD ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Wu CW ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Application of a biodegradable macromolecular contrast agent in dynamic contrast-enhanced MRI for assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy. ------>language=1 ------>check_flag=None ------>submit_date=None ------>country=NULL ------>no=4 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2007 ------>submit_flag=None ------>publish_month=12 |